Incidence and Severity of Covid-19 in Patients with and without Previously Verified Infections with Common Cold Coronaviruses.
作者信息
Ringlander Johan, Martner Anna, Nilsson Staffan, Westin Johan, Lindh Magnus, Hellstrand Kristoffer
机构信息
Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden.
Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
出版信息
J Infect Dis. 2021 May 28;223(10):1831-1832. doi: 10.1093/infdis/jiab089.
Abstract
摘要
相似文献
1
Incidence and Severity of Covid-19 in Patients with and without Previously Verified Infections with Common Cold Coronaviruses.既往确诊感染或未感染普通感冒冠状病毒的患者中新冠病毒病的发病率和严重程度
J Infect Dis. 2021 May 28;223(10):1831-1832. doi: 10.1093/infdis/jiab089.
2
[Not Available].[无可用内容]
Rev Med Suisse. 2020 Jul 15;16(700):1394.
3
Patients with Common Cold Coronaviruses Tested Negative for IgG Antibody to SARS-CoV-2.普通感冒冠状病毒患者的新冠病毒IgG抗体检测呈阴性。
J Clin Microbiol. 2020 Jul 23;58(8). doi: 10.1128/JCM.01029-20.
4
How COVID-19 is changing the cold and flu season.新冠病毒如何改变感冒和流感季节。
Nature. 2020 Dec;588(7838):388-390. doi: 10.1038/d41586-020-03519-3.
5
Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus.学校中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的物理距离措施与鼻病毒的再度流行
Lancet Respir Med. 2020 Dec;8(12):e92-e93. doi: 10.1016/S2213-2600(20)30502-6. Epub 2020 Oct 22.
6
Prior infection with intestinal coronaviruses moderates symptom severity and mortality in patients with COVID-19: A hypothesis and preliminary evidence.肠道冠状病毒既往感染可减轻 COVID-19 患者的症状严重程度和死亡率：假说和初步证据。
Med Hypotheses. 2020 Oct;143:110116. doi: 10.1016/j.mehy.2020.110116. Epub 2020 Jul 18.
7
Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1).COVID-19 病情较轻与针对季节性人类冠状病毒 OC43 和 HKU1（HCoV OC43、HCoV HKU1）的抗体水平升高有关。
Int J Infect Dis. 2021 Apr;105:304-306. doi: 10.1016/j.ijid.2021.02.085. Epub 2021 Feb 23.
8
How kids' immune systems can evade COVID.儿童的免疫系统如何抵御新冠病毒。
Nature. 2020 Dec;588(7838):382. doi: 10.1038/d41586-020-03496-7.
9
Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.静脉注射免疫球蛋白制剂中的抗 SARS-CoV-2 抗体：与季节性冠状病毒、天然自身免疫反应的交叉反应性及其治疗意义。
Front Immunol. 2021 Feb 17;12:627285. doi: 10.3389/fimmu.2021.627285. eCollection 2021.
10
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.COVID-19 和 SARS 病例以及未感染对照者的 SARS-CoV-2 特异性 T 细胞免疫。
Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15.
引用本文的文献
1
Does Prior Respiratory Viral Infection Provide Cross-Protection Against Subsequent Respiratory Viral Infections? A Systematic Review and Meta-Analysis.先前的呼吸道病毒感染是否能提供针对随后的呼吸道病毒感染的交叉保护作用？系统评价和荟萃分析。
Viruses. 2024 Jun 19;16(6):982. doi: 10.3390/v16060982.
2
Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms.三种不同新冠疫苗平台诱导的针对新冠病毒变异株以及季节性人类冠状病毒NL63、HKU1和229E的抗体中和活性分析
Vaccines (Basel). 2022 Dec 27;11(1):58. doi: 10.3390/vaccines11010058.
3
Role of the humoral immune response during COVID-19: guilty or not guilty?体液免疫反应在 COVID-19 中的作用：有罪还是无罪？
Mucosal Immunol. 2022 Jun;15(6):1170-1180. doi: 10.1038/s41385-022-00569-w. Epub 2022 Oct 4.
4
Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization.早期且在正确位置采取行动：SARS-CoV-2 细胞动力学和组织定位。
Int J Mol Sci. 2022 Sep 14;23(18):10679. doi: 10.3390/ijms231810679.
5
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic.COVID-19 大流行不断变化的格局中的 SARS-CoV-2 特异性 T 细胞。
Immunity. 2022 Oct 11;55(10):1764-1778. doi: 10.1016/j.immuni.2022.08.008. Epub 2022 Aug 18.
6
The past, current and future epidemiological dynamic of SARS-CoV-2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的过去、当前及未来流行病学动态
Oxf Open Immunol. 2022 Jun 20;3(1):iqac003. doi: 10.1093/oxfimm/iqac003. eCollection 2022.
7
Human seasonal coronavirus neutralization and COVID-19 severity.人类季节性冠状病毒中和作用与 COVID-19 严重程度。
J Med Virol. 2022 Oct;94(10):4820-4829. doi: 10.1002/jmv.27937. Epub 2022 Jul 18.
8
Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia.澳大利亚健康成年人中 HCoV-NL63 中和抗体的流行率。
Viruses. 2021 Aug 16;13(8):1618. doi: 10.3390/v13081618.
9
Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities.COVID-19 患者不同疾病严重程度下对季节性人类冠状病毒的交叉反应性体液免疫应答。
Int J Infect Dis. 2021 Oct;111:68-75. doi: 10.1016/j.ijid.2021.08.026. Epub 2021 Aug 15.
10
Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19.反复接触亚感染剂量的 SARS-CoV-2 可能会促进 T 细胞免疫并预防重症 COVID-19。
Viruses. 2021 May 22;13(6):961. doi: 10.3390/v13060961.
Zotero 插件